Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fsd Pharma Inc Cl B (NQ: HUGE )

0.0899 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fsd Pharma Inc Cl B

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
FSD Pharma Inc. Board Approves Share Repurchase Program
FSD Pharma (NASDAQ: HUGE), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, is repurchasing up to 2 million company shares. The... 
Via Benzinga
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board Approves Share Repurchase Program
Via Investor Brand Network
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board Approves Share Repurchase Program
Via Investor Brand Network
FSD Pharma Announces Share Repurchase Program
From FSD Pharma Inc.
Via Business Wire
Mobile Clinics for Mental Health Treatments Reportedly Launching in Major Cities Across the U.S.
Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... 
Via Benzinga
FSD Pharma Announces Establishment of Advisory Board, Strategic Appointments
FSD Pharma (NASDAQ: HUGE), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced that it has formed a regulatory... 
Via Benzinga
FSD Pharma Shares Preclinical Data Demonstrating Positive Effects of Lucid-MS in Treating
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today shared preclinical data... 
Via Benzinga
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) Shares Preclinical Data Demonstrating Positive Effects of Lucid-MS in Treating MS
Via Investor Brand Network
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) Announces Establishment of Advisory Board, Strategic Appointments
Via Investor Brand Network
FSD Pharma Establishes New Regulatory Advisory Board with the Appointment of Joga Gobburu, Ph.D., and Mary Melnyk, Ph.D., as Members
From FSD Pharma Inc.
Via Business Wire
FSD Pharma to Present at the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th
From FSD Pharma Inc.
Via Business Wire
FSD Pharma Unveils Videos Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis in Pre-Clinical Models (Mouse Models)
From FSD Pharma Inc.
Via Business Wire
FSD Pharma Expands Research and Clinical Advisory Board with Appointment of World-Renowned Immunologist and Cytokine Expert Dr. Eleanor N. Fish
From FSD Pharma Inc.
Via Business Wire
Ketamine’s Potential As A Treatment For Depression Has Drawn Major Industry Attention
Palm Beach, FL –October 27, 2021 – FinancialNewsMedia.com News Commentary – Among the race to see what psychedelic drugs can do, ketamine is a step ahead of all other drugs, because it has already been... 
Via FinancialNewsMedia
Exposures Product Safety
FSD Pharma Signs Agreement with Covar Pharmaceuticals to Support the Development of Lucid-PSYCH
From FSD Pharma Inc.
Via Business Wire
FSD Pharma Announces Engagement with Capital Markets Communications Providers and Market Maker
From FSD Pharma Inc.
Via Business Wire
FSD Pharma Announces Closing of Lucid Psycheceuticals Acquisition
From FSD Pharma Inc.
Via Business Wire
Psyched: Cybin Gets $9 Price Target, FSD Pharma Acquires Lucid, New Trials From Psilera, Awakn, PharmaDrug And Braxia, California Bill Put On Hold
Contents 
Via Benzinga
Nasdaq-listed FSD Pharma To Advance Psychedelics Pipeline With $9 Million Acquisition Of Lucid Psycheceuticals
FSD Pharma Inc. (NASDAQ:HUGE) (CSE: 
Via Benzinga
FSD Pharma To Buy Canadian Psychedelic Pharmaceutical Firm
FSD Pharma Inc (NASDAQ: HUGE) shares rebounded after falling in premarket on acquiring a Canada-based psychedelic pharmaceutical company. Related: See Why FSD Pharma... 
Via Benzinga
54 Biggest Movers From Yesterday
Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares jumped 202.8% to settle at $46.33 on Wednesday after gaining over 11% on Tuesday. Regencell Bioscience recently... 
Via Benzinga
36 Stocks Moving In Wednesday's Mid-Day Session
Gainers Locust Walk Acquisition Corp. (NASDAQ: LWAC) shares jumped 188% to $25.34 after the company announced stockholders approved a business combination with eFFECTOR... 
Via Benzinga
FSD Pharma Announces Definitive Agreement to Acquire Lucid Psycheceuticals
From FSD Pharma Inc.
Via Business Wire
See Why FSD Pharma Terminated COVID-19 Trial
FSD Pharma Inc (NASDAQ: HUGE) will terminate the Phase 2 trial of ultra-micronized palmitoylethanolamide (PEA), or FSD-201, for COVID-19. FSD-201 works by... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug
ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
Exposures COVID-19
21 Stocks Moving in Wednesday's Pre-Market Session
Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) rose 40.1% to $21.43 in pre-market trading after gaining over 11% on Tuesday. Regencell Bioscience recently reported... 
Via Benzinga
FSD Pharma Inc. Announces Termination of FSD-201 Phase 2 Clinical Trial
From FSD Pharma Inc.
Via Business Wire
FSD Pharma Inc. Announces Termination of Chief Executive Officer Dr. Raza Bokhari for Cause
From FSD Pharma Inc.
Via Business Wire
64 Biggest Movers From Friday
Gainers Senseonics Holdings, Inc. (NYSE: SENS) jumped 42% to settle at $2.91 on Friday after the company disclosed results from a PROMISE study evaluating its Eversense CGM... 
Via Benzinga
40 Stocks Moving In Friday's Mid-Day Session
Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares jumped 68.8% to $25.49 after gaining 23% on Thursday. Senseonics Holdings, Inc. (NYSE: SENS) gained 26% to $2.5817 after the... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.